Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 691–700 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 691
- Medicine slug
- glucagon
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 17
- Source count
- 4
- Agreement rate
- 0.5
- Recorded readings
137-2425 L
- Numeric value
- 137
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:359982a8-ec5c-4927-8c0f-89771e0f942b (opens source in a new tab)
Glucagon label
Version not recorded · Effective date not recorded
Figure 3: : Plasma Glucagon Concentration (mean ± standard error of the mean) vs. Time After Subcutaneous Administration of 1 mg of GVOKE in Adults with Type 1 Diabetes Mellitus Distribution The apparent volume of distribution was in the range of 137-2425 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92385737-dbad-98c5-e053-2995a90a2805 (opens source in a new tab)
Glucagon label
Version not recorded · Effective date not recorded
Figure 3: : Plasma Glucagon Concentration (mean ± standard error of the mean) vs. Time After Subcutaneous Administration of 1 mg of GVOKE in Adults with Type 1 Diabetes Mellitus Distribution The apparent volume of distribution was in the range of 137-2425 L.
885 L
- Numeric value
- 885
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1f5df9b-872f-44e5-a18f-f0b68e7e9254 (opens source in a new tab)
Glucagon label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution was approximately 885 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32ba41fa-4158-40af-8cb2-03693c248994 (opens source in a new tab)
Glucagon label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution was approximately 885 L.
Projected row 692
- Medicine slug
- glyburide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 37
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a56f100f-0f42-4188-81ab-04644b824040 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf21c8c0-7247-4d5b-97f8-ae4016144642 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec45f0d8-cab8-4822-895b-17bb443a4f98 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87781ea8-62ec-483c-a4dd-8c965ce59485 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:922d1080-52c6-41e4-a310-533d8ca18594 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a12342fb-123c-2951-e053-2a95a90ac596 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9cdd30e7-512a-4f00-a4de-0a154d143ce9 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:901c50d5-31e7-b073-e053-2995a90abfeb (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f65131c-90df-45ab-95fb-c36f411c6fbe (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33418bba-c5ea-4c0f-9d28-31dc2724c6c3 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b292cb9b-7348-4c07-a871-bc091229fdf8 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5de0ef6-4c8b-40ab-b0ed-2003a8086750 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:676c0e45-0aa2-4060-ad18-67abb9873a50 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:240c3ac6-9aab-4185-994e-a0254e3aeb61 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50d16f1d-c814-4411-8749-62561321ecce (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic, the terminal half-life being about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1233548-bbb8-34aa-e053-2a95a90aea53 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25516c2a-f1b5-9ee4-e063-6394a90ab46b (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9cb9251-7b31-72a0-e053-2a95a90a4315 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffd31d06-6011-34e2-e053-6394a90a437f (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e354b4d-70e4-5089-e054-00144ff88e88 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d0e406f-285d-4716-8971-82f665345517 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51cf08e2-8a2f-4bde-996f-f431f1a68abd (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db47a517-f8bb-136f-e053-2a95a90ad8c5 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:524eec41-37ee-419a-b7a1-d23e888ae6ab (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc8df889-25e0-49a0-bbec-a3dfae8bbb8a (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a280f88-26d4-4fe5-a89b-a6f1d90ed3cd (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c91a408-973b-4572-832f-515f61d5be1f (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4573af7f-3c71-e323-e063-6394a90aa9eb (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e661288-2d24-4403-86a1-754afa1d04ff (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d090f978-b1a5-4db7-951d-3f32dd06966c (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e23b9a3b-0184-4d1c-8e2c-668697a6da87 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ee41cd3-461f-3408-e053-2991aa0a863d (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea7a055b-64f0-46bf-aa8e-4a2ef5c3c035 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21786ac0-da3c-16cb-e063-6394a90a4596 (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05341afe-5b7a-462a-a196-689cb09f83fc (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db074991-1267-454a-8b1d-b6f52e2132cc (opens source in a new tab)
Glyburide label
Version not recorded · Effective date not recorded
The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours.
Projected row 693
- Medicine slug
- glycerol-phenylbutyrate
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
81%
- Numeric value
- 81
- Unit
- %
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e78f2dfd-fb39-4e4b-a639-64591d282ca6 (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
/day) 70 (79) 50 (1 to 410) Adults (n=43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) *micrograms/mL Distribution In vitro , the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bfa912f-c86c-4702-ac99-464c4356d80c (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
5 to 15.1 g/m 2 /day) 70 (79) 50 (1 to 410) Adults (n=43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) Distribution In vitro , the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3b52ded-b305-445c-b943-ef0fb2dedd2b (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
/day) 70 (79) 50 (1 to 410) Adults (n=43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) *micrograms/mL Distribution In vitro , the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c094cb63-3aa0-4564-9c53-7e78f2a56367 (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
/day) 70 (79) 50 (1 to 410) Adults (n=43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) *micrograms/mL Distribution In vitro , the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:900e7dc0-9afe-4f50-80de-90567bb78519 (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
to 15.1 g/m 2 /day) 70 (79) 50 (1 to 410) Adults (n = 43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) Distribution In vitro , the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11981aec-dbf1-4906-acfd-3c10708fe0a6 (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
/day) 70 (79) 50 (1 to 410) Adults (n=43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) *micrograms/mL Distribution In vitro , the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4dc2c81-3b30-4bb8-af7d-4d093981c386 (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
2 /day) 70 (79) 50 (1 to 410) Adults (n=43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) *micrograms/mL Distribution In vitro, the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28bb5ec0-a99f-4774-b8a8-b6c229b89ba5 (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
/day) 70 (79) 50 (1 to 410) Adults (n=43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) *micrograms/mL Distribution In vitro , the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15c4da9f-f5e0-4628-b55f-3730be3e1c39 (opens source in a new tab)
Glycerol Phenylbutyrate label
Version not recorded · Effective date not recorded
/day) 70 (79) 50 (1 to 410) Adults (n=43) 0.6 to 14 mL/m 2 /day (0.7 to 15.4 g/m 2 /day) 39 (40) 25 (1.6 to 178) *micrograms/mL Distribution In vitro , the extent of plasma protein binding for 14 C-labeled metabolites was 81% to 98% for PBA (over 1 to 250 micrograms/mL), and 37% to 66% for PAA (over 5 to 500 micrograms/mL).
Projected row 694
- Medicine slug
- glycopyrrolate
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 117
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
3%
- Numeric value
- 3
- Unit
- %
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4741be85-3abb-4545-aba9-281f64d210ec (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e6f8091-d6fe-4c8f-b897-606a70bf74bc (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3% to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98820c01-1853-45d8-9da5-875fcdf5f9ab (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff65c5d3-7ba9-4315-a884-199151eb45a5 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7049feaf-004a-481f-b129-996b21c3170a (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e20c9a89-2a81-3c6e-e053-2995a90a9861 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed22456b-b488-49ec-b96b-2541f5f3c955 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d200bd44-9856-4104-a29e-a4cca3db6737 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89090b34-470c-478c-be49-1d2bc48a28f8 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f05c5d3-9c41-4dae-88d1-18cbddc69487 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e58f860b-e955-4d71-a128-93bd3812b08d (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:579d2499-6520-41fb-ae52-f3d8b9af8950 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b3f8b3e-6fa8-471b-8bee-3dac5e3ea1b8 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:512d3f1e-c35c-87c2-e063-6394a90a8de0 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3% to 13.3%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b493d7-8e3b-e459-e063-6394a90addbc (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).
Projected row 695
- Medicine slug
- glycopyrrolate
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 117
- Source count
- 15
- Agreement rate
- 0.8
- Recorded readings
3.0 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4741be85-3abb-4545-aba9-281f64d210ec (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98820c01-1853-45d8-9da5-875fcdf5f9ab (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff65c5d3-7ba9-4315-a884-199151eb45a5 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7049feaf-004a-481f-b129-996b21c3170a (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for Glycopyrrolate Oral Solution was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e20c9a89-2a81-3c6e-e053-2995a90a9861 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate oral solution was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed22456b-b488-49ec-b96b-2541f5f3c955 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d200bd44-9856-4104-a29e-a4cca3db6737 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for CUVPOSA was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89090b34-470c-478c-be49-1d2bc48a28f8 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e58f860b-e955-4d71-a128-93bd3812b08d (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:579d2499-6520-41fb-ae52-f3d8b9af8950 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b3f8b3e-6fa8-471b-8bee-3dac5e3ea1b8 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b493d7-8e3b-e459-e063-6394a90addbc (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e6f8091-d6fe-4c8f-b897-606a70bf74bc (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f05c5d3-9c41-4dae-88d1-18cbddc69487 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for Glycopyrrolate oral solution was 3.1 hours, and mean plasma half-life was 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:512d3f1e-c35c-87c2-e063-6394a90a8de0 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3 hours.
Projected row 696
- Medicine slug
- glycopyrrolate
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 117
- Source count
- 76
- Agreement rate
- 0.802632
- Recorded readings
0.42 ± 0.22 L/kg
- Numeric value
- 0.42
- Unit
- L/kg
- Source records
- 61
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 61 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e76bc0e4-68f5-70b4-e053-2a95a90a451e (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f12016d-9033-00b4-e053-2a95a90ad02a (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54458620-d888-4df6-ae4b-78c3dfed3423 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bde90dd-0300-f705-e053-2a95a90a7ea6 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2972f22e-378c-450b-8869-1354a9bd0ffc (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65688bed-0d70-4b51-8301-1948b1deade1 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:871797f0-697a-4a29-a37b-d06219e8f266 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a46c5ec1-a1b4-46fc-9b37-8da7f0c983d6 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ac4f32f-f5ca-4a6d-9bc7-2672d478b3d4 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ecb3435-58e5-46cb-b8c2-85b5fd955f83 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:327f8a9e-7730-4f38-a7aa-fbddebddf173 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:685aaf64-1a64-42f9-a96f-4764d650c26f (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbab4cf1-0441-4fc4-9de9-e4117fa19faa (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0933e843-df2a-3d32-e063-6394a90a1037 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9be0ad4e-3efa-1a24-e053-2995a90a60d5 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02f914a8-2356-4525-91ff-cf0c9e41ba23 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9df3900-a8c2-438b-8971-ba11ff91f90b (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5a18d74-0d40-46e2-aa0a-41d18609a536 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaebb511-1738-4d11-b9bb-317a8d41316a (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccafb5c2-86dd-4bb2-883a-c13e3171227c (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:225d95b4-7f8f-44c2-8fc2-93b75d9cc651 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2189f3f5-39dc-4e85-b7c6-9515ded59686 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2a2a03f-21cc-5fec-e053-2995a90a84cb (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f126596-7fbf-7a48-e053-2995a90abac7 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea4c8be4-a1e9-5901-e053-2995a90a5e63 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f777c813-3232-d744-8bcf-58e86fb929bd (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3707f06a-6cba-4f5c-86ab-fb95bc2a933c (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d670bd26-8a44-44be-90e1-107d4c380233 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62267afe-1a73-4623-984e-646db590ec5b (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution: The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a3a142c-daaf-79af-e053-2995a90a1c51 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3edcc39d-0e29-4585-e063-6394a90ad512 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74d51ba3-0ca0-4a04-aa87-1c243f885bd8 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b4d1798-c0a7-4661-99cd-1e9a23c16386 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b335c67-4f8f-47e5-abfc-f8c2c15496d7 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83d70378-011b-4ce3-e053-2991aa0a22be (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02541cfd-b209-49b9-a73f-13ef18dce06d (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86abf577-562c-5eb1-e053-2a91aa0ac10f (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c9666bf-841b-03fa-e053-2a95a90abb48 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f2b4281-55f3-43e3-e063-6294a90a56ba (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cb1ecbe-1e7a-4b39-8e1d-0c20f145e177 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb1ae370-ec4f-4114-9860-8f736f72b545 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f4a4b94-71e0-49ed-8f1e-c760e4dd3137 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:765490fa-8378-40c8-9fa7-b0bfa2e1a0a9 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f7f1ebf-58e8-4ae7-8157-1595df8ad6f4 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88d3e865-8dca-4c89-b6f7-a34c481f75b9 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e5113b7-1c0c-24bd-e053-2995a90ab94b (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8bb95ed-09f1-fcf1-e053-2a95a90a93e5 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:430635e8-7c9e-77f6-e063-6294a90a4c8a (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:516cc4f8-3583-4405-ab66-29d4fcc56d05 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bb2fa8a-3318-1e9a-2c79-8371bcae3d1c (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbf0abe2-8deb-19b2-e053-2a95a90a60a3 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c3be3a-ea28-864f-e053-2a95a90a701a (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95fbe384-eaff-1f2e-e053-2a95a90a0313 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:250eeef7-b1a9-45e7-a927-7807232e10be (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83602e34-7a8c-4606-b43e-23ab909b6c1a (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29618edf-39b0-022a-9875-9d865450d318 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b622f21f-fa37-1259-e053-2995a90aa796 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ±0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55930f87-8964-43b1-b790-c1e6dd2602d2 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:741355f5-b695-41bb-a065-4abc687312b2 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3edd6a26-dd0f-2411-e063-6394a90affa2 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960d2dd0-008d-4ec1-ba2e-9388b28b23e2 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
DISTRIBUTION The mean volume of distribution of glycopyrrolate was estimated to be 0.42 ± 0.22 L/kg.
1.3 to 1.8 L/kg
- Numeric value
- 1.3
- Unit
- L/kg
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4741be85-3abb-4545-aba9-281f64d210ec (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13* 3.2 ± 1.1* * n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98820c01-1853-45d8-9da5-875fcdf5f9ab (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
.09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13* 3.2 ± 1.1* *n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff65c5d3-7ba9-4315-a884-199151eb45a5 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
1.09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13* 3.2 ±1.1* *n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7049feaf-004a-481f-b129-996b21c3170a (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
± 1.09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13 n=35 3.2 ± 1.1 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e20c9a89-2a81-3c6e-e053-2995a90a9861 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13* 3.2 ± 1.1* * n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed22456b-b488-49ec-b96b-2541f5f3c955 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13* 3.2 ± 1.1* * n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d200bd44-9856-4104-a29e-a4cca3db6737 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
± 1.09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13 n=35 3.2 ± 1.1 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89090b34-470c-478c-be49-1d2bc48a28f8 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13 * 3.2 ± 1.1 * * n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f05c5d3-9c41-4dae-88d1-18cbddc69487 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
1.09 3.0 ± 1.2 Fed (n=36) 0.084 ±0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13* 3.2 ± 1.1* *n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e58f860b-e955-4d71-a128-93bd3812b08d (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
± 1.09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13 n=35 3.2 ± 1.1 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:579d2499-6520-41fb-ae52-f3d8b9af8950 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
1.81± 1.09 3.0± 1.2 Fed (n=36) 0.084± 0.081 2.60± 1.12 0.38± 0.14 0.46± 0.13* 3.2±1.1* *n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b3f8b3e-6fa8-471b-8bee-3dac5e3ea1b8 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
81 ± 1.09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13* 3.2 ± 1.1* Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b493d7-8e3b-e459-e063-6394a90addbc (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
09 3.0 ± 1.2 Fed (n=36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13* 3.2 ± 1.1* * n=35 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg.
1.3 L/kg
- Numeric value
- 1.3
- Unit
- L/kg
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e6f8091-d6fe-4c8f-b897-606a70bf74bc (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
.09 3.0 ± 1.2 Fed (n = 36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13 n = 35 3.2 ± 1.1 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 year to 14 years of approximately 1.3 L/kg to 1.8 L/kg, with a range from 0.7 L/kg to 3.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:512d3f1e-c35c-87c2-e063-6394a90a8de0 (opens source in a new tab)
Glycopyrrolate label
Version not recorded · Effective date not recorded
.09 3.0 ± 1.2 Fed (n = 36) 0.084 ± 0.081 2.60 ± 1.12 0.38 ± 0.14 0.46 ± 0.13 n = 35 3.2 ± 1.1 Distribution After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 year to 14 years of approximately 1.3 L/kg to 1.8 L/kg, with a range from 0.7 L/kg to 3.9 L/kg.
Projected row 697
- Medicine slug
- goserelin
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
27.3%
- Numeric value
- 27.3
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:294b168b-6e5f-4db9-bf70-d599271458b3 (opens source in a new tab)
Goserelin label
Version not recorded · Effective date not recorded
The plasma protein binding of goserelin obtained from one sample was found to be 27.3%.
27%
- Numeric value
- 27
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4cb3c20-2738-400a-b522-3f36f71fe6c5 (opens source in a new tab)
Goserelin label
Version not recorded · Effective date not recorded
The plasma protein binding of goserelin was found to be 27%.
Projected row 698
- Medicine slug
- granisetron
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 10
- Source count
- 5
- Agreement rate
- 0.8
- Recorded readings
8.95 hours
- Numeric value
- 8.95
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b713d3-7ca8-465a-aefa-65ddbe17b934 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
to 9.14] 6.23 [0.96 to 19.9] 3.94 [1.89 to 39.4] 0.41 [0.11 to 24.6] 1 Not determined after oral administration; following a single intravenous dose of 40 mcg/kg, terminal phase half-life was determined to be 8.95 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2758eb4d-2fe0-4f74-b3f5-b4903009e97c (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Table 1 Pharmacokinetic Parameters (Median [range]) Following Kytril Tablets 1 Not determined after oral administration; following a single intravenous dose of 40 mcg/kg, terminal phase half-life was determined to be 8.95 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df4b6775-4337-41e0-815a-b064d98c3fe1 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Not determined after oral administration; following a single intravenous dose of 40 mcg/kg, terminal phase half-life was determined to be 8.95 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2be8de3-04fe-4e92-82b4-98d749b89596 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Table 1: Pharmacokinetic Parameters (Median [range]) Following Granisetron hydrochloride Tablets * Not determined after oral administration; following a single intravenous dose of 40 mcg/kg, terminal phase half-life was determined to be 8.95 hours.
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7c7ffdd-8270-4030-bc1e-a1cb28a6de56 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Elimination Metabolism: Following a single 10 mg subcutaneous injection of SUSTOL, the terminal elimination half-life of granisetron was approximately 24 hours and was comparable between healthy subjects and patients.
Projected row 699
- Medicine slug
- granisetron
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
65%
- Numeric value
- 65
- Unit
- %
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:783e9d68-2371-4fd4-8d7a-a5e36f8718d0 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
4.91 † 0.88 to 15.2 0.79 † 0.2 to 2.56 3.04 † 1.68 to 6.13 65 to 81 years Mean Range 57 † 14.6 to 153 7.69 † 2.65 to 17.7 0.44 † 0.17 to 1.06 3.97 † 1.75 to 7.01 Distribution Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7379369a-03df-4ec3-8f2e-66645cc736d8 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Figure Distribution Plasma protein binding is approximately 65%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b713d3-7ca8-465a-aefa-65ddbe17b934 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dddc8714-383f-4bc5-a468-ae89dbc802b4 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7c7ffdd-8270-4030-bc1e-a1cb28a6de56 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of granisetron is approximately 65% and granisetron distributes freely between plasma and red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2758eb4d-2fe0-4f74-b3f5-b4903009e97c (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07862df-f324-4575-a1ef-f7e1cbab4c7a (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
79 3.04 Range 11.2 to 182 0.88 to 15.2 0.20 to 2.56 1.68 to 6.13 65 to 81 years Mean 57.0 7.69 0.44 3.97 Range 14.6 to 153 2.65 to 17.7 0.17 to 1.06 1.75 to 7.01 Distribution Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d88adba-7f5e-4e97-84b3-6ca8ec98c023 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
0.79 3.04 Range 11.2 to 182 0.88 to 15.2 0.20 to 2.56 1.68 to 6.13 65 to 81 years Mean 57 7.69 0.44 3.97 Range 14.6 to 153 2.65 to 17.7 0.17 to 1.06 1.75 to 7.01 Distribution Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df4b6775-4337-41e0-815a-b064d98c3fe1 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2be8de3-04fe-4e92-82b4-98d749b89596 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.
Projected row 700
- Medicine slug
- granisetron
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 10
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7c7ffdd-8270-4030-bc1e-a1cb28a6de56 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Injection Site Location Abdomen N=113 Upper Arm N=113 C max (ng/mL) 9.8 ± 4.8 10.8 ± 4.6 T max (hours) [range] 12 [1 to 144] 11 [1 to 120] AUC inf , ng.h/mL 680 ± 362 720 ± 366 In patients, peak plasma granisetron concentrations were delayed compared to healthy subjects with a median T max of approximately 24 hours.
48 hours
- Numeric value
- 48
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7379369a-03df-4ec3-8f2e-66645cc736d8 (opens source in a new tab)
Granisetron label
Version not recorded · Effective date not recorded
Following the application of a single 6-day SANCUSO 52 cm 2 transdermal system, in healthy male Japanese subjects, mean C max , AUC (0-144) , and AUC (0-∞) values were 5.02 ng/mL (CV: 66%), 492 ng.hr/mL (CV: 72%), and 562 ng.hr/mL (CV: 60%), respectively, and a median t max value was 48 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=690Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.